Influence of rifaximin treatment on the susceptibility of intestinal Gram-negative flora and enterococci.

No abstract is available for this paper.

• Publication year

  2004

• Venue

  Clinical Microbiology and Infection

• Publication date

  2004-11-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1111/J.1469-0691.2004.00997.XPMID 15522005
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Therapy of travelers’ diarrhea with rifaximin on various continents

  2003cited by this paper
• In Vitro Antimicrobial Susceptibility Testing of Bacterial Enteropathogens Causing Traveler's Diarrhea in Four Geographic Regions

  2001influential reference
• Comparison of two non-absorbable antibiotics for treatment of bacterial enteritis in children.

  1998cited by this paper
• Rifaximin, a non-absorbable rifamycin, for the treatment of hepatic encephalopathy. A double-blind, randomised trial.

  1997cited by this paper
• Selection of rifampicin-resistant Mycobacterium tuberculosis does not occur in the presence of low concentrations of rifaximin.

  1997cited by this paper
• Rifaximin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic potential in conditions mediated by gastrointestinal bacteria.

  1995cited by this paper
• Antimicrobial activity and spectrum of rifaximin, a new topical rifamycin derivative.

  1993cited by this paper
• Prevention and treatment of traveler's diarrhea.

  1993cited by this paper
• Treatment of Small Intestine Bacterial Overgrowth with Rifaximin, a Non-Absorbable Rifamycin

  1988cited by this paper
• Rifampin: spectrum of antibacterial activity.

  1983cited by this paper
• Emergence of high-level trimethoprim resistance in fecal Escherichia coli during oral administration of trimethoprim or trimethoprim-sulfamethoxazole.

  1982cited by this paper
• Emergence of high-level trimethoprim resistance in fecal Escherichia coli during oral administration of trimethoprim or trimethoprim--sulfamethoxazole.

  1982cited by this paper
• Principles and practice of infectious diseases. Vols 1 and 2.

  1979cited by this paper

• Exploring the Prevalence, Predictors, and Impact of Bacterial Infections to Guide Empiric Antimicrobial Decisions in Cirrhosis (EPIC-AD).

  2024cites this paper
• The potential for development of clinically relevant microbial resistance to rifaximin-α: a narrative review

  2023cites this paper
• Improving Management of Portal Hypertension: The Potential Benefit of Non-Etiological Therapies in Cirrhosis

  2023cites this paper
• Efficacy of a 1 day Rifaximin and Metronidazole Regimen and Mechanical Bowel Preparation for Preventing Surgical Site Infection in Minimally Invasive Colorectal Cancer Surgery: A Prospective Observational Study

  2023cites this paper
• The role of microbiota and its modulation in colonic diverticular disease

  2023cites this paper
• Rifaximin Vs. Norfloxacin for Spontaneous Bacterial Peritonitis Prophylaxis: A Randomized Controlled Trial.

  2021cites this paper
• Rifaximin microbial resistance and its efficacy and safety as a secondary prophylaxis of hepatic encephalopathy in patients with hepatitis C virus‐related cirrhosis

  2021cites this paper
• Medikamentöse Langzeittherapien zur Prognoseverbesserung bei Leberzirrhose und zur Vermeidung von Komplikationen der portalen Hypertension

  2019cites this paper
• Aktualisierte S2k-Leitlinie der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) „Komplikationen der Leberzirrhose“

  2019cites this paper
• Aktualisierte S2k-Leitlinie der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) „Komplikationen der Leberzirrhose“

  2019cites this paper
• TREATMENT OF IBS-D CASES THROUGH RIFAXIMIN

  2019cites this paper
• Novel Antimicrobials for the Treatment of Clostridium difficile Infection

  2018cites this paper
• A CROSS-SECTIONAL ANALYTICAL RESEARCH STUDY TO VERIFY THE OUTCOMES OF RIFIXAMIN AT VICTIMS OF DYSPEPTIC BOWEL SYNDROME THROUGH PRE-DOMINANT DIARRHEA AT SERVICES HOSPITAL, LAHORE

  2018cites this paper
• Role of Rifaximin in Spontaneous Bacterial Peritonitis Prevention

  2018cites this paper
• COMPARISON OF RIFAXIMIN, LACTULOSE WITH RIFAXIMIN, LACTULOSE, BRANCHED CHAIN AMINOACIDS (BCAA) IN GRADE 1 TO GRADE 3 OF HEPATIC ENCEPHALOPATHY- NON RANDOMIZED CONTROLLED TRIAL STUDY

  2017cites this paper
• Rifaximin for the prevention of spontaneous bacterial peritonitis and hepatorenal syndrome in cirrhosis: a systematic review and meta-analysis

  2017cites this paper
• Susceptibility to rifaximin and other antimicrobials of bacteria isolated in patients with acute gastrointestinal infections in Southeast Mexico.

  2017cites this paper
• Susceptibility to rifaximin and other antimicrobials of bacteria isolated in patients with acute gastrointestinal infections in Southeast Mexico

  2017cites this paper
• Repeat Rifaximin for Irritable Bowel Syndrome: No Clinically Significant Changes in Stool Microbial Antibiotic Sensitivity

  2017cites this paper
• Systematic review with meta‐analysis: rifaximin for the prophylaxis of spontaneous bacterial peritonitis

  2017cites this paper
• Rifamycin SV MMX for the treatment of traveler’s diarrhea

  2017cites this paper
• Human brucellosis in France in the 21st century: Results from national surveillance 2004-2013.

  2016cites this paper
• Use of rifaximin in gastrointestinal and liver diseases.

  2016cites this paper
• Efficacy and safety of alternating norfloxacin and rifaximin as primary prophylaxis for spontaneous bacterial peritonitis in cirrhotic ascites: a prospective randomized open-label comparative multicenter study

  2016cites this paper
• Infectious Considerations in the Pre-Transplant Evaluation of Cirrhotic Patients Awaiting Orthotopic Liver Transplantation

  2016cites this paper
• New and emerging therapies for the treatment of irritable bowel syndrome: an update for gastroenterologists

  2016cites this paper
• Susceptibilidad de las bacterias aisladas de infecciones gastrointestinales agudas a la rifaximina y otros agentes antimicrobianos en México

  2016cites this paper
• The role of rifaximin in the chemoprophylaxis of travelers ’ diarrhoea particularly aiming at the first 2 weeks of travel : a meta-analysis of 5 randomized , double-blind , controlled trials

  2016cites this paper
• Rifaximin: A reasonable alternative for norfloxacin in the prevention of spontaneous bacterial peritonitis in patients with HCV-related liver cirrhosis

  2016cites this paper
• Susceptibility to rifaximin and other antimicrobial agents of bacteria isolated from acute gastrointestinal infections in Mexico

  2016cites this paper
• Review article: the antimicrobial effects of rifaximin on the gut microbiota

  2016cites this paper
• Rifaximin for the treatment of irritable bowel syndrome – a drug safety evaluation

  2016cites this paper
• Susceptibility of bacteria isolated from acute gastrointestinal infections to rifaximin and other antimicrobial agents in Mexico.

  2016cites this paper
• University of Birmingham Spontaneous bacterial peritonitis

  2015cites this paper
• Spontaneous bacterial peritonitis: The clinical challenge of a leaky gut and a cirrhotic liver.

  2015cites this paper
• Safety and tolerability of rifaximin for the treatment of irritable bowel syndrome without constipation: a pooled analysis of randomised, double‐blind, placebo‐controlled trials

  2014cites this paper
• Impact of Rifaximin on the Frequency and Characteristics of Spontaneous Bacterial Peritonitis in Patients with Liver Cirrhosis and Ascites

  2014cites this paper
• Resistència antimicrobiana en patògens bacterians causants de diarrea: recerca d’alternatives

  2014cites this paper
• University of Impact of rifaximin on the frequency and characteristics of spontaneous bacterial peritonitis in patients with liver cirrhosis and ascites

  2014cites this paper
• Rifaximin-Mediated Changes to the Epithelial Cell Proteome: 2-D Gel Analysis

  2013cites this paper
• Use of Rifaxamin in Patients of Irritable Bowel Syndrome with Pre Dominant Diarrhea

  2013cites this paper
• Rifaximin in the Treatment of Irritable Bowel Syndrome: Is There a High Risk for Development of Antimicrobial Resistance?

  2013cites this paper
• The Effect of Rifaximin on Gut Flora and Staphylococcus Resistance

  2013cites this paper
• Rifaximin Resistance in Escherichia coli Associated with Inflammatory Bowel Disease Correlates with Prior Rifaximin Use, Mutations in rpoB, and Activity of Phe-Arg-β-Naphthylamide-Inhibitable Efflux Pumps

  2012cites this paper
• The Role of Rifaximin in the Primary Prophylaxis of Spontaneous Bacterial Peritonitis in Patients With Liver Cirrhosis

  2012cites this paper
• Efficacy of rifaximin in prevention of travelers' diarrhea: a meta-analysis of randomized, double-blind, placebo-controlled trials.

  2012cites this paper
• Rifaximin

  2012cites this paper
• Non-absorbed Antibiotics for IBS

  2012cites this paper
• Intestinal decontamination inhibits TLR4 dependent fibronectin-mediated cross-talk between stellate cells and endothelial cells in liver fibrosis in mice.

  2012cites this paper
• Refractory Clostridium difficile Infection Successfully Treated with Tigecycline, Rifaximin, and Vancomycin

  2012cites this paper
• Rifaximin Therapy of Irritable Bowel Syndrome

  2012cites this paper
• High prevalence of antibiotic-resistant bacterial infections among patients with cirrhosis at a US liver center.

  2012cites this paper
• Impact of rifaximin use for hepatic encephalopathy on the risk of early post‐transplant infections in liver transplant recipients

  2012cites this paper
• Serum Antibodies Protect against Intraperitoneal Challenge with Enterotoxigenic Escherichia coli

  2011cites this paper
• Rifaximin: new therapeutic indication and future directions.

  2011cites this paper
• Rifaximin for the treatment of acute infectious diarrhea

  2011cites this paper
• Rifaximin for irritable bowel syndrome without constipation.

  2011cites this paper
• Current use for old antibacterial agents: polymyxins, rifamycins, and aminoglycosides.

  2011cites this paper
• Rifaximin – ein nicht resorbierbares Antibiotikum mit vielfältigen Anwendungsmöglichkeiten in der Gastroenterologie

  2011cites this paper
• Spontaneous bacterial peritonitis: recent guidelines and beyond

  2011cites this paper
• Non-Absorbed Antibiotic for Irritable Bowel Syndrome

  2011cites this paper
• Rifaximin for irritable bowel syndrome without constipation.

  2011cites this paper
• [Rifaximin--a non-resorbable antibiotic with many indications in gastroenterology].

  2011cites this paper
• Rifaximin in the treatment of hepatic encephalopathy

  2011cites this paper
• Biologic properties and clinical uses of rifaximin

  2011cites this paper
• Rifaximin: a nonsystemic rifamycin antibiotic for gastrointestinal infections

  2010cites this paper
• Review article: rifaximin, a minimally absorbed oral antibacterial, for the treatment of travellers’ diarrhoea

  2010cites this paper
• In Vitro Antimicrobial Susceptibility of Bacterial Enteropathogens Isolated from International Travelers to Mexico, Guatemala, and India from 2006 to 2008

  2010cites this paper
• Rifaximin treatment in hepatic encephalopathy.

  2010cites this paper
• Rifaximin-induced alteration of virulence of diarrhoea-producing Escherichia coli and Shigella sonnei.

  2010cites this paper
• Rifaximin for the treatment of hepatic encephalopathy

  2010cites this paper
• Prevention and Treatment of Travelers' Diarrhea

  2010cites this paper
• A rifaximina no tratamento da encefalopatia hepática

  2010cites this paper
• Therapeutic Success of Rifaximin for Clostridium difficile Infection Refractory to Metronidazole and Vancomycin

  2010cites this paper
• Bile Acids Improve the Antimicrobial Effect of Rifaximin

  2010cites this paper
• Prevention of travelers' diarrhea with rifaximin in US travelers to Mexico.

  2010cites this paper
• Local antimicrobial therapy with rifaximin : A novel perspective for irritable bowel syndrome

  2009cites this paper
• Pretreatment of Epithelial Cells with Rifaximin Alters Bacterial Attachment and Internalization Profiles

  2009cites this paper
• Expert review of the evidence base for prevention of travelers' diarrhea.

  2009cites this paper
• Small Intestinal Bacterial Overgrowth: Novel Insight in the Pathogenesis and Treatment of Irritable Bowel Syndrome

  2009cites this paper
• Systematic review: prevention of travellers’ diarrhoea

  2008cites this paper
• Travelers' Diarrhea, New Insights

  2007cites this paper
• Treatment of travelers' diarrhea: randomized trial comparing rifaximin, rifaximin plus loperamide, and loperamide alone.

  2007cites this paper
• Pretransplant management of the cirrhotic patient.

  2007cites this paper
• Rifaximin treatment of pathogen-negative travelers' diarrhea.

  2007cites this paper
• Prevention and Treatment of Traveler’s Diarrhea

  2006cites this paper
• Rifaximin, a nonabsorbed oral antibiotic, prevents shigellosis after experimental challenge.

  2006cites this paper
• Utility of the Nonabsorbed (<0.4%) Antibiotic Rifaximin in Gastroenterology and Hepatology.

  2006cites this paper
• A Randomized Double-Blind Placebo-Controlled Trial of Rifaximin in Patients with Abdominal Bloating and Flatulence

  2006cites this paper
• Prevention and treatment of traveler's diarrhea. Focus on antimicrobial agents.

  2006cites this paper
• Safety and Tolerability of the Antibacterial Rifaximin in the Treatment of Travellers’ Diarrhoea

  2006cites this paper
• Experimental and Clinical Pharmacology of Rifaximin, a Gastrointestinal Selective Antibiotic

  2006cites this paper
• Rifaximin: a novel nonabsorbed rifamycin for gastrointestinal disorders.

  2006cites this paper
• Rifaximin, a Poorly Absorbed Antibiotic: Pharmacology and Clinical Potential

  2005cites this paper
• Antibacterial chemoprophylaxis in the prevention of traveler's diarrhea: evaluation of poorly absorbed oral rifaximin.

  2005cites this paper
• Rifaximin: a novel antimicrobial for enteric infections

  2005cites this paper
• Current concepts in travelers' diarrhea: epidemiology, antimicrobial resistance and treatment

  2005cites this paper
• A Randomized, Double-Blind, Placebo-Controlled Trial of Rifaximin To Prevent Travelers' Diarrhea

  2005cites this paper
• Rifaximin: In vitro and in vivo Antibacterial Activity – A Review

  2005cites this paper
• Travelers' diarrhea: antimicrobial therapy and chemoprevention

  2005cites this paper